NCT01279291 - Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

NeoplasmsOvarian NeoplasmsFallopian Tube NeoplasmsPrimary Peritoneal Neoplasm

Interventions

BIOLOGICAL

KHK2866

Potentially therapeutic monoclonal antibody for the treatment of advanced cancer and ovarian cancer.

DRUG

Gemcitabine and Carboplatin

Combination chemotherapy with KHK2866 to treat advanced platinum-sensitive ovarian cancer. Gemcitabine dose 1000 mg/m2, Carboplatin dose AUC=4

DRUG

paclitaxel

Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. Paclitaxel will be administered weekly at a dose of 80 mg/m2.

DRUG

pegylated liposomal doxorubicin

Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. PLD will be administered weekly at a dose of 40 mg/m2.

Trial Locations (7)

77030

Oncology Consultants, Houston

78229

Cancer Therapy and Research Center, San Antonio

85724

Arizona Cancer Center, Tucson

90033

USC Norris Comprehensive Cancer Center, Los Angeles

90048

Cedar Sinai-Samuel Oschin Comprehensive Cancer Institute, Los Angeles

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston